ESCRS - POREF072 - Keratorefractive Lenticule Extraction (Klex) For Moderate Hyperopia: Visual And Refractive Outcomes

Keratorefractive Lenticule Extraction (Klex) For Moderate Hyperopia: Visual And Refractive Outcomes

Published 2026 - 44th Congress of the ESCRS

Reference: POREF072 | Type: Free paper | DOI: 10.82333/9qnh-nz83

Authors: A/Prof. Smita Agarwal* 1 , Dr Erin Thornell 2 , Ms Lily Chang 2 , Mr Dakota Williams 2

1Graduate school of medicine,University of Wollongong,Wollongong,Australia;Ophthalmology,Central Sydney Clinical School ,Sydney,Australia, 2Ophthalmology,Wollongong Eye Specialists,Wollongong,Australia

Purpose

While KLEx is well established as a safe and predictable treatment for myopic refractive error, treatment of hyperopia has only recently become possible. This study will review clinical records of eyes that have undergone KLEx for the treatment of moderate hyperopia to assess early visual and refractive results, providing valuable insight into real-world clinical outcomes.

Setting

Private refractive surgery in NSW, Australia. (Wollonong Refractive Laser Eye Institute WRLEI)

Methods

A retrospective review was performed for 13 eyes from 7 patients who underwent KLEx for the treatment of hyperopia. Four eyes underwent partial correction (mean target 1.0±0.84 D, range +0.5 to +2.25 D dependent on residual corneal thickness) and the remaining eyes underwent full correction. Postoperative assessment performed at 4-6 weeks in all eyes and 3 eyes up to 12 months included manifest refraction, uncorrected and best-corrected distance visual acuity (BCVA).

Results

Of those eyes that underwent full correction, mean postoperative manifest refraction spherical equivalent (MRSE) was -0.29±0.38 D, and mean uncorrected distance visual acuity (UDVA) was 0.04±0.07 LogMAR. For eyes that underwent partial correction, mean postoperative MRSE was +0.11±0.40 D and mean postoperative UDVA was 0.07±0.09 LogMAR. Mean BCVA was 0.01±0.03 LogMAR for all eyes, with 92% achieving within ±0.5 D of target MRSE. No intra- or post-operative complications were reported, and no eyes required further touch up.

 

 

Conclusions

These results indicate that KLEx can offer safe and predictable treatment of hyperopia. Further investigation of larger long-term data sets is required to establish long-term stability.